Free Trial
NASDAQ:WGS

GeneDx (WGS) Stock Price, News & Analysis

GeneDx logo
$81.69
-1.51 (-1.81%)
(As of 10/31/2024 ET)

About GeneDx Stock (NASDAQ:WGS)

Key Stats

Today's Range
$77.69
$83.30
50-Day Range
$29.62
$84.02
52-Week Range
$1.16
$89.11
Volume
781,807 shs
Average Volume
438,132 shs
Market Capitalization
$2.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.33
Consensus Rating
Moderate Buy

Company Overview

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

GeneDx Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
24th Percentile Overall Score

WGS MarketRank™: 

GeneDx scored higher than 24% of companies evaluated by MarketBeat, and ranked 906th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    GeneDx has only been the subject of 3 research reports in the past 90 days.

  • Read more about GeneDx's stock forecast and price target.
  • Earnings Growth

    Earnings for GeneDx are expected to grow in the coming year, from ($0.75) to $0.14 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GeneDx is -18.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GeneDx is -18.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    GeneDx has a P/B Ratio of 9.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about GeneDx's valuation and earnings.
  • Percentage of Shares Shorted

    12.55% of the float of GeneDx has been sold short.
  • Short Interest Ratio / Days to Cover

    GeneDx has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in GeneDx has recently increased by 8.60%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    GeneDx does not currently pay a dividend.

  • Dividend Growth

    GeneDx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.55% of the float of GeneDx has been sold short.
  • Short Interest Ratio / Days to Cover

    GeneDx has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in GeneDx has recently increased by 8.60%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    GeneDx has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 28 news articles for GeneDx this week, compared to 3 articles on an average week.
  • Search Interest

    26 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 189% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,770,553.00 in company stock.

  • Percentage Held by Insiders

    27.30% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GeneDx's insider trading history.
Receive WGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter.

WGS Stock News Headlines

$5k to $1.3m in just 3 trades
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
GeneDx price target raised to $95 from $70 at Craig-Hallum
GeneDx price target raised to $95 from $45 at BTIG
GeneDx price target raised to $75 from $34 at Wells Fargo
See More Headlines

WGS Stock Analysis - Frequently Asked Questions

GeneDx's stock was trading at $2.75 at the start of the year. Since then, WGS shares have increased by 2,870.5% and is now trading at $81.69.
View the best growth stocks for 2024 here
.

GeneDx Holdings Corp. (NASDAQ:WGS) posted its earnings results on Monday, November, 15th. The company reported $4.95 earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.27) by $11.22. The firm had revenue of $43.18 million for the quarter, compared to analysts' expectations of $42 million. GeneDx had a negative net margin of 48.21% and a negative trailing twelve-month return on equity of 22.71%.

GeneDx's stock reverse split on the morning of Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Top institutional investors of GeneDx include Assenagon Asset Management S.A. (1.26%), Raymond James & Associates (0.73%), Principal Financial Group Inc. (0.05%) and Precision Wealth Strategies LLC (0.03%). Insiders that own company stock include Casdin Capital, Llc, Opko Health, Inc, Tactical Opportunit Blackstone, Jason Ryan, Kevin Feeley, Kareem Saad, Richard C Pfenniger Jr, Daniel Emmett Clark, Isaac Ro, Eric Schadt, Karen Ann White, Shawn Assad, Richard Miao and Anthony Prentice.
View institutional ownership trends
.

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

Last Earnings
11/15/2021
Today
10/31/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/18/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Health services
Sub-Industry
Healthcare
Current Symbol
NASDAQ:WGS
Fax
N/A
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.33
High Stock Price Target
$95.00
Low Stock Price Target
$21.00
Potential Upside/Downside
-28.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-175,770,000.00
Pretax Margin
-48.56%

Debt

Sales & Book Value

Annual Sales
$267.23 million
Book Value
$8.78 per share

Miscellaneous

Free Float
19,582,000
Market Cap
$2.23 billion
Optionable
Optionable
Beta
2.32
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:WGS) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners